The FDA has approved Lusedra (fospropofol disodium, from Eisai), an intravenous sedative-hypnotic agent, for monitored anesthesia care (MAC) sedation in adults undergoing diagnostic or therapeutic procedures. In the approval, the FDA required that Lusedra be used only by persons trained in administering general anesthetics. Lusedra patients should be continuously monitored by persons not involved in the conduct of the procedure.

For more information call (888) 274-2378 or visit www.eisai.com.